-
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
in PRESS RELEASE 2022 onFerring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees…
-
Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray
in STATEMENT 2022 onFollowing the detection of out-of-specification results during testing, in 2020 Ferring initiated a precautionary voluntary global recall of all batches of the following products: Minirin® (desmopressin) Nasal Spray 0.1 mg/ml…
-
Ferring Announces New Collaboration for Development of Olamkicept
in PRESS RELEASE 2022 onFerring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
in PRESS RELEASE 2022 onNew subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.
-
Panicked and overwhelmed: NEW study reveals the emotional and psychological impact of infertility
in PRESS RELEASE 2022 onNew research published in Reproductive Biomedicine, has found that 60% of people believe that the diagnosis and treatment of infertility has impacted their mental health. This impact on mental health has been found to increase with treatment duration and…
-
Ferring delivered record results in 2021 and is on course for future ambitions
in NEWS 2022 onFerring today published its latest Annual Report which shows the company reported revenues of €2,162 million, +11% at AER, +14% at CER and a record level of Net Income at €290 million up +91% AER. These results reflect the company’s strong and leading position in the field…
-
Ferring announces leadership appointments to drive next phase of growth
in NEWS 2022 onFerring has announced key leadership appointments to ensure it is well-placed to deliver on the next exciting phase of its growth strategy. This includes developing and launching new therapies in the field of reproductive medicine and maternal health and other specialty areas of medicine such as…
-
Ferring statement on the Ukraine crisis
in STATEMENT 2022 onAs we witness the escalating humanitarian crisis caused by the war in Ukraine, Ferring continues to stand by the people impacted and support those in need. As a healthcare company with a purpose to build families and help people live better lives, we are supporting three major emergency relief efforts…
-
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme
in PRESS RELEASE 2022 onForensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals…
-
Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth
in PRESS RELEASE 2021 onAfter nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH)…
Author archive for celia
Articles by: celia
